Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. (ELVN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ELVN · as of Sep 30, 2025
Ownership Breakdown
133
Institutional Holders
▲ 10 vs Q2
$1.22B
Total Inst. Value
▲ $23.44M vs Q2
60.90M
Shares Outstanding
freeFloat 58.26%
59.39M
13F Shares Held
▼ 45,412 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ELVN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC pharmaceutical preparations | 7.96M | 12.82% | 12.82% | $162.93B | Nov 14, 2025 | — held |
FMR LLC pharmaceutical preparations | 7.13M | 11.48% | 11.48% | $145.93B | Nov 13, 2025 | ▼ 430.7K |
COMMODORE CAPITAL LP pharmaceutical preparations | 4.69M | 7.56% | 7.56% | $96.06B | Nov 14, 2025 | — held |
FAIRMOUNT FUNDS MANAGEMENT LLC pharmaceutical preparations | 3.71M | 5.98% | 5.98% | $75.97B | Nov 14, 2025 | — held |
BLACKROCK, INC. pharmaceutical preparations | 3.52M | 5.67% | 5.67% | $72.02B | Nov 12, 2025 | ▲ 551.4K |
VR ADVISER, LLC pharmaceutical preparations | 3.23M | 5.20% | 5.20% | $66.04B | Nov 14, 2025 | ▼ 800.0K |
POLAR CAPITAL HOLDINGS PLC pharmaceutical preparations | 3.10M | 4.98% | 4.98% | $63.35B | Nov 14, 2025 | ▲ 44.7K |
VANGUARD GROUP INC pharmaceutical preparations | 2.55M | 4.11% | 4.11% | $52.26B | Nov 7, 2025 | ▲ 142.4K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 1.79M | 2.89% | 2.89% | $36.70B | Nov 14, 2025 | ▲ 77.2K |
NOVO HOLDINGS A/S pharmaceutical preparations | 1.43M | 2.30% | 2.30% | $29.20B | Nov 14, 2025 | ▲ 341.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
28
Increased
+4.59M shares1
New Positions
first time holders11
Decreased
−3.06M shares0
Sold Out
fully exitedNet shares change (top 50)
+1.53M
+4.59M / −3.06M
Net new holders
+18
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ELVN insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
8
Sell transactions
0.25
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Collins Helen Louise CHIEF MEDICAL OFFICER | May 18, 2026 | Sale | 3,475 | $39.53 | $137.4K | 26.5K | Form 4 ↗ |
Collins Helen Louise CHIEF MEDICAL OFFICER | May 18, 2026 | Sale | 1,302 | $40.25 | $52.4K | 25.2K | Form 4 ↗ |
Collins Helen Louise CHIEF MEDICAL OFFICER | May 18, 2026 | Sale | 223 | $41.21 | $9.2K | 25.0K | Form 4 ↗ |
Collins Helen Louise CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale | 140 | $45.81 | $6.4K | 29.9K | Form 4 ↗ |
Collins Helen Louise CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale | 2,419 | $47.39 | $114.6K | 27.4K | Form 4 ↗ |
Collins Helen Louise CHIEF MEDICAL OFFICER | Apr 17, 2026 | Sale | 2,441 | $48.06 | $117.3K | 25.0K | Form 4 ↗ |
Collins Helen Louise CHIEF MEDICAL OFFICER | Mar 25, 2026 | Sale | 40,000 | $35.10 | $1.40M | 25.0K | Form 4 ↗ |
Collins Helen Louise CHIEF MEDICAL OFFICER | Mar 17, 2026 | Sale | 5,000 | $27.76 | $138.8K | 25.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Enliven Therapeutics, Inc. (ELVN) is primarily owned by institutional investors, who hold approximately 97.5% of total shares outstanding. Company insiders own approximately 41.74%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Enliven Therapeutics, Inc. is ORBIMED ADVISORS LLC, holding approximately 7.96 million shares — equal to 12.82% of outstanding shares — as of September 30, 2025.
A total of 133 institutional investors currently hold ELVN stock, with a combined institutional value of approximately $1.22 billion as of the most recent 13F filing period.
Frequently asked questions
ELVN ownershipEnliven Therapeutics, Inc. (ELVN) is primarily owned by institutional investors, who hold approximately 97.5% of shares. The largest shareholder is ORBIMED ADVISORS LLC with a 12.82% stake. Company insiders hold 41.74%. Data sourced from SEC Form 13F as of September 30, 2025.